Keros Therapeutics, Inc. financial data

Symbol
KROS on Nasdaq
Industry
Pharmaceutical Preparations
Location
1050 Waltham Street, Suite 302, Lexington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.91K % -7.29%
Debt-to-equity 8.93 % +6.69%
Return On Equity -44.7 % -6.02%
Return On Assets -41.1 % -5.47%
Operating Margin -69.6K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.5M shares +26.5%
Common Stock, Shares, Outstanding 36.2M shares +21.9%
Entity Public Float 905M USD +92.3%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36.1M shares +22%
Weighted Average Number of Shares Outstanding, Diluted 36.1M shares +22%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 271K USD
Research and Development Expense 150M USD +37.3%
General and Administrative Expense 38.5M USD +25.8%
Operating Income (Loss) -189M USD -34.6%
Nonoperating Income (Expense) 20.6M USD +51.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD -84.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -168M USD -32.8%
Earnings Per Share, Basic -5.13 USD/shares -13%
Earnings Per Share, Diluted -5.13 USD/shares -13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 406M USD +26%
Accounts Receivable, after Allowance for Credit Loss, Current 4K USD
Other Assets, Current 582K USD +54.8%
Assets, Current 433M USD +29.4%
Property, Plant and Equipment, Net 4.29M USD +39%
Operating Lease, Right-of-Use Asset 14.6M USD -8.5%
Other Assets, Noncurrent 2.16M USD +36.9%
Assets 455M USD +27.7%
Accounts Payable, Current 6.54M USD +57.6%
Employee-related Liabilities, Current 5.31M USD +30.3%
Accrued Liabilities, Current 13.6M USD +13.9%
Liabilities, Current 21.2M USD +32%
Operating Lease, Liability, Noncurrent 12.9M USD -7.81%
Liabilities 34.1M USD +13.5%
Retained Earnings (Accumulated Deficit) -470M USD -55.7%
Stockholders' Equity Attributable to Parent 421M USD +29%
Liabilities and Equity 455M USD +27.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.6M USD -30.2%
Net Cash Provided by (Used in) Financing Activities 157M USD +45.6%
Net Cash Provided by (Used in) Investing Activities -946K USD +10.9%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 36.2M shares +21.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 111M USD +53.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 407M USD +25.9%
Deferred Tax Assets, Valuation Allowance 99.4M USD +63.9%
Deferred Tax Assets, Gross 103M USD +58.9%
Operating Lease, Liability 14.4M USD +8.88%
Depreciation 277K USD +65.9%
Payments to Acquire Property, Plant, and Equipment 946K USD -10.9%
Lessee, Operating Lease, Liability, to be Paid 21.4M USD +5.86%
Property, Plant and Equipment, Gross 5.85M USD +83.9%
Operating Lease, Liability, Current 1.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.5M USD +13.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.43M USD +39.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.92M USD +0.06%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.58M USD
Deferred Tax Assets, Operating Loss Carryforwards 36.2M USD -3.83%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.58M USD +10.3%
Operating Lease, Payments 500K USD +150%
Additional Paid in Capital 891M USD +41.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.66M USD -13.2%
Share-based Payment Arrangement, Expense 32.9M USD +48%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares